Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Equities researchers at Oppenheimer increased their FY2017 earnings per share (EPS) estimates for shares of Neurocrine Biosciences in a report released on Monday, according to Zacks Investment Research. Oppenheimer analyst J. Olson now expects that the company will post earnings per share of ($1.40) for the year, up from their prior forecast of ($1.59). Oppenheimer has a “Buy” rating and a $95.00 price target on the stock. Oppenheimer also issued estimates for Neurocrine Biosciences’ Q4 2017 earnings at $0.28 EPS, Q4 2018 earnings at $0.95 EPS, FY2018 earnings at $1.08 EPS, FY2019 earnings at $1.41 EPS, FY2020 earnings at $5.44 EPS and FY2022 earnings at $8.56 EPS.
Several other research analysts have also recently issued reports on the stock. Jefferies Group increased their price target on shares of Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a report on Friday, January 5th. BMO Capital Markets upped their target price on shares of Neurocrine Biosciences from $83.00 to $109.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Needham & Company LLC restated a “buy” rating and set a $86.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Leerink Swann restated an “outperform” rating and set a $83.00 target price (up from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Barclays upped their target price on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, November 2nd. One analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $84.13.
Neurocrine Biosciences (NASDAQ NBIX) traded up $0.71 during midday trading on Thursday, reaching $79.28. 958,400 shares of the company traded hands, compared to its average volume of 1,020,000. The stock has a market capitalization of $7,020.00, a PE ratio of -35.71, a P/E/G ratio of 13.14 and a beta of 0.26. Neurocrine Biosciences has a 52-week low of $39.21 and a 52-week high of $91.82. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05.
In related news, Director William H. Rastetter sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $90.00, for a total transaction of $855,000.00. Following the sale, the director now owns 34,250 shares in the company, valued at $3,082,500. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Darin Lippoldt sold 9,900 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total transaction of $723,195.00. The disclosure for this sale can be found here. Insiders sold 189,707 shares of company stock worth $14,975,715 over the last quarter. Company insiders own 4.80% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Mission Wealth Management LP purchased a new position in shares of Neurocrine Biosciences in the 4th quarter valued at $204,000. Stanley Laman Group Ltd. raised its stake in shares of Neurocrine Biosciences by 60.8% in the 4th quarter. Stanley Laman Group Ltd. now owns 89,146 shares of the company’s stock valued at $6,917,000 after acquiring an additional 33,723 shares during the period. American International Group Inc. purchased a new stake in Neurocrine Biosciences during the 4th quarter worth $161,000. Virtus Fund Advisers LLC increased its stake in Neurocrine Biosciences by 234.0% during the 4th quarter. Virtus Fund Advisers LLC now owns 17,726 shares of the company’s stock worth $1,375,000 after buying an additional 12,419 shares during the period. Finally, Wells Fargo & Company MN increased its stake in Neurocrine Biosciences by 2.1% during the 4th quarter. Wells Fargo & Company MN now owns 965,449 shares of the company’s stock worth $74,909,000 after buying an additional 20,081 shares during the period.
ILLEGAL ACTIVITY NOTICE: “Neurocrine Biosciences, Inc. to Post FY2017 Earnings of ($1.40) Per Share, Oppenheimer Forecasts (NBIX)” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://ledgergazette.com/2018/02/12/oppenheimer-comments-on-neurocrine-biosciences-inc-s-fy2017-earnings-nbix.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.